
- /
- Supported exchanges
- / US
- / IMRX.NASDAQ
Immuneering Corp (IMRX NASDAQ) stock market data APIs
Immuneering Corp Financial Data Overview
Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Immuneering Corp data using free add-ons & libraries
Get Immuneering Corp Fundamental Data
Immuneering Corp Fundamental data includes:
- Net Revenue: 455
- EBITDA: -63 850 176
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-06
- EPS/Forecast: -0.585
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Immuneering Corp News

Immuneering director Schall buys $89k in IMRX stock
Director Thomas J. Schall of Immuneering Corp (NASDAQ:IMRX) recently purchased 40,485 shares of Class A Common Stock, according to a Form 4 filing with the Securities and Exchange Commission. The tr...


Immuneering stock price target raised to $10 at Mizuho on cancer drug data
Mizuho raised its price target on Immuneering Corporation (NASDAQ:IMRX) to $10.00 from $8.00 on Wednesday, while maintaining an Outperform rating following positive clinical trial results for the co...

Immuneering stock rises after positive pancreatic cancer trial data
Investing.com -- Immuneering Corporation (NASDAQ:IMRX) stock rose 7% on Monday after the clinical-stage oncology company reported positive survival data from its ongoing Phase 2a trial evaluating at...

Why Immuneering Is Rising In Pre-market?
(RTTNews) - Immuneering (IMRX) announced positive data from ongoing Phase 2a clinical trial evaluating atebimetinib, an oral, once-daily MEK inhibitor, in combination with modified gemcitabine/nab-pac...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.